.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Federal Trade Commission
Fuji
Boehringer Ingelheim
Chubb
McKesson
US Army
QuintilesIMS
AstraZeneca
Citi

Generated: February 23, 2018

DrugPatentWatch Database Preview

Patents Expiring in August 2031

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ironwood Pharms IncDUZALLOallopurinol; lesinuradTABLET;ORAL209203-002Aug 18, 2017RXYesYes➤ Sign Up➤ Sign UpTREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
Ironwood Pharms IncDUZALLOallopurinol; lesinuradTABLET;ORAL209203-001Aug 18, 2017RXYesNo➤ Sign Up➤ Sign UpTREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
Ironwood Pharms IncZURAMPIClesinuradTABLET;ORAL207988-001Dec 22, 2015RXYesYes➤ Sign Up➤ Sign UpCOADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%
Clovis Oncology IncRUBRACArucaparib camsylateTABLET;ORAL209115-001Dec 19, 2016RXYesNo➤ Sign Up➤ Sign UpA METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
Astrazeneca PharmsLYNPARZAolaparibCAPSULE;ORAL206162-001Dec 19, 2014RXYesYes➤ Sign Up➤ Sign UpTREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-002Aug 17, 2017RXYesYes➤ Sign Up➤ Sign UpTREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY BASED ON AN FDA-APPROVED COMPANION DIAGNOSTIC FOR LYNPARZA
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-002Aug 17, 2017RXYesYes➤ Sign Up➤ Sign UpMAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-001Aug 17, 2017RXYesNo➤ Sign Up➤ Sign UpMAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
Astrazeneca PharmsLYNPARZAolaparibTABLET;ORAL208558-001Aug 17, 2017RXYesNo➤ Sign Up➤ Sign UpTREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY BASED ON AN FDA-APPROVED COMPANION DIAGNOSTIC FOR LYNPARZA
Flexion Theraps IncZILRETTAtriamcinolone acetonideFOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR208845-001Oct 6, 2017RXYesYes➤ Sign Up➤ Sign UpY
This preview shows a limited number of results
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
QuintilesIMS
Daiichi Sankyo
Cantor Fitzgerald
Dow
Cerilliant
Chinese Patent Office
Harvard Business School
Chubb
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot